China set to give a big boost to biologics

INICIO/Políticas y legislación | Posted 24/09/2010 post-comment0 Post your comment

According to a report in a Chinese newspaper, China is planning to spend more than CNY 10 billion (US$1.5 billion) to support the development of new drugs between 2011 and 2016. Biotechnology was identified as one of seven emerging industries that China will use to spearhead the next big step in its economic development.


“The development plan for the industries has been submitted to the National Development and Reform Commission and may be announced as soon as the end of this month”, the newspaper reported.

This is not the first time China has stepped in to boost its biotechnology industry. Back in March 2009 the Chinese government announced plans to spend at least CNY 62.8 billion (US$9.2 billion) by the end of 2010 on 11 national research programmes (including biotechnology) to achieve breakthroughs in key technology development.

China is continuing to be attractive as a place to outsource active pharmaceutical ingredients (APIs). Boehringer Ingelheim is the latest in a line of Big Pharma to open a centre in China in order to optimise API and chemical intermediates sourcing.

However, how long China’s appeal will last as reduced tax rebates, correction of the currency rate and increasing wages chip away at China’s cost advantage remains to be seen.

Related article

Is China set to lose its low-cost appeal?

References [homepage on Internet]. [Accessed 2010 September 9].

China to invest billions on key technology development, bio industry.

National Development and Reform Commission (NDRC). People’s Republic of China [homepage on Internet]. [Accessed 2010 September 9].

comment icon Comments (0)
Post your comment
Related content
Consulta pública para la modificación de la regulación de biosimilares
02 AA010638
INICIO/Políticas y legislación Posted 16/01/2024
COFEPRIS promueve la cooperación regulatoria en América
Latin America 1638px
INICIO/Políticas y legislación Posted 12/12/2023
Pendiente la decisión de ANVISA sobre las ‘skinny labels’ para genéricos
Labelling V14I26
INICIO/Políticas y legislación Posted 14/11/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010